Efavirenz: shifting the HAART paradigm in adult HIV-1 infection

Bibliography

• BHIVA: Guidelines Co-Ordinating Committee. British HIVassociation guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet (1997) 349:1086–1092.
   Google Scholar
• CARPENTER CJ, FISCHL MA, HAMMER SM et al.: Antiretro-viral therapy for HIV infection in 1998. JAMA (1998) 280:78–86.
   PubMed Web of Science ®Google Scholar
• MOYLE GJ: Viral resistance patterns selected by antiret-roviral drugs and their potential to guide treatment choice. Exp. Opin. Invest. Drugs (1997) 6:943–964.
   PubMedGoogle Scholar
• CARR A, SAMARAS K, BURTON S, LAW M, FREUND J, CHI-SOLM DJ, COOPER DA: A syndrome of peripheral lipo-dystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 12:F51–F58.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive description of clinical and metabolic distur-bances observed during PI therapy.
   Google Scholar
• MOYLE G, GAZZARD BG: Assessment of risk versus benefit for therapeutic intervention with HIV protease inhibitors. Drug Safety (1999). (In Press).
   Google Scholar
• •Objective survey of the frequency of adverse events with PI and the decision making process in therapy.
   Google Scholar
• RABEL SR, MAURIN MB, ROWE SM, HUSSAIN M: Determi-nation of the pKa and p11-solubility behavior of an ionizable cyclic carbamate, (5)-0-6-Chloro-4-(cyclo-p ro py 1 e t hy ny 0-4 - (triflouro methyl) -2, 4 -dihydro-11-1-3, 1-benzoxazin-2-one (DMP266). Pharm. Dev. Technol. (1996) 1:91–95.
   PubMedGoogle Scholar
• ERICKSON JW, BURT SK: Structural mechanisms of HIVdrug resistance. Ann. Rev. Pharmacol. Toxicol. (1996) 36:545–571.
   PubMed Web of Science ®Google Scholar
• D'AQUILLA RT: 11IV-1 drug resistance: molecular patho-genesis and laboratory monitoring. Clinics Lab. Med. (1994) 14:393–423.
   PubMed Web of Science ®Google Scholar
• ARNOLD E, DING J, HUGHES SH, HOSTOMSKY Z: Struc-tures of DNA and RNA polymerases and their interac-tions with nucleic acid substrates. Curr. Opin. Struct. Biol. (1995) 5:27–38.
   PubMed Web of Science ®Google Scholar
• KOHLSTAEDT LA, WANG J, FRIEDMAN JM, RICE PA, STEITZ TA: Crystal structure at 3.5A resolution of 11IV-1 reverse transcriptase complexed with an inhibitor. Science (1992) 256:1783–1790.
   Google Scholar
• YOUNG SD, BRITCHER SF, TRAN OL et al.: L-743, 726 (DMP-266): a novel, highly potent non-nucleoside in-hibitor of the human immunodeficiency virus Type 1 reverse transcriptase. Antimicrob. Agents Chem other. (1995) 39:2602–2605.
   PubMed Web of Science ®Google Scholar
• ••Main published article on efavirenz summarising preclinicalattributes.
   Google Scholar
• JEFFERY S, BAKER D, TRITCH R, RIZZO C, LOGUE K, BACHELER L: A resistance and cross-resistance profile for Sustiva (Efavirenz, DMP 266). 5th Conference on Ret-roviruses and Opportunistic Infections. Chicago, USA (1–5 Feb. 1998). Abstract 702.
   Google Scholar
• FISKE WD, BRENNAN JM, HAINES PJ, MUTLIB AE, GEMZIK B, GERSON R: Efavirenz (DMP 266) cerebrospinal fluid (CSF) concentrations after chronic oral administra-tion to cynomologous monkeys. 5th Conference on Ret-roviruses and Opportunistic Infections. Chicago, USA (1–5 Feb. 1998). Abstract 640.
   Google Scholar
• BACHELOR LT, ANTON E, BAKER D et al: Impact of muta-tion, plasma protein binding and pharmacokinetics on clinical efficacy of the 11IV-1 non nucleoside re-verse transcriptase inhibitor, DMP 266. 37th ICAAC. To-ronto, Canada (28 Sept.-1 Oct. 1997). Abstract 1–115.
   Google Scholar
• JOSHI A, FISKE WD, BENEDEK IH et al.: Lack of pharma-cokinetic interaction between Efavirenz (DMP 266) and ethinyl estradiol in healthy volunteers. 5th Confer-ence on Retro viruses and Opportunistic Infections. Chicago, USA (1–5 Feb. 1998). Abstract 348.
   Google Scholar
• GRAUL A, RABASSEDA X, CASTANER J: Efavirenz. Drugs of the future (1998) 23:133–141.
   Google Scholar
• MAYERS D, RIDDLER S, STEIN D, BACH M, HAVLIR D, KAHN J: A double-blind pilot study to evaluate the an-tiviral activity, tolerability and pharmacokinetics of DMP 266 alone and in combination with indinavir. 36th ICAAC. New Orleans, USA (15–18 Sept. 1996). Abstract LB8a.
   Google Scholar
• FISKE WD, BENEDEK IH, JOSEPH JL et al.: Pharmacoki-netics of efavirenz (EFV) and ritonavir (IITV) after mul-tiple oral doses in healthy volunteers. 12th World AIDS Conference. Geneva, Switzerland (28 June-3 July 1998). Ab-stract 42269.
   Google Scholar
• BENEDEK IH, JOSHI A, FISKE WD et al. Pharmacokinetic interaction between efavirenz (EFV) and rifampin (RIF) in healthy volunteers. 12 thWorld AIDS Conference Geneva, Switzerland (28 June-3 July 1998) Abstract 42280
   Google Scholar
• BENEDEK IH, JOSHI A, FISKE WD et al: Pharmacokinetic(PK) interaction studies in healthy volunteers with efavirenz (EFV) and the macrolide antibiotics, Azithro-mycin (AZM) and clarithromycin (CLR). 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1–5 Feb. 1998). Abstract 347.
   Google Scholar
• FISKE WD, BENEDEK IH, WHITE SJ, JOSEPH JL, KORN-HAUSER DM: Pharmacokinetic interaction between DMP 266 and nelfinavir mesylate (NFV) in healthy vol-unteers. 37th ICAAC. Toronto, Canada (Sept. 1997). Ab-stract I–174.
   Google Scholar
• FISKE WD, MAYERS D, WAGNER K etal.: Pharmacokinet-ics of DMP 266 and indinavir multiple oral doses in 11IV-1 infected individuals. 4th Conference on Retrovi-ruses and Opportunistic Infections. Washington, USA (22–26 Jan. 1997). Abstract.
   Google Scholar
• WINSLOW DL, GARBER S, REID C et al: Selection condi-tions affect the evolution of specific mutations in re-verse transcriptase gene associated with resistance to DMP 266. AIDS (1996) 10:1205–1209.
   PubMed Web of Science ®Google Scholar
• BACHELOR L, GEORGE H, HOLLIS G et al.: Resistance toefavirenz (Sustiva) in vivo. 5th Conference on Retrovi-ruses and Opportunistic Infections. Chicago, USA (1–5 Feb. 1998). Abstract 703.
   Google Scholar
• •Relationship between phenotypic, and genotypic resistance to efavirenz and failure.
   Google Scholar
• BACHELOR LT, ANTON E, JEFFREY S et al: RT gene muta- tions associated with resistance to efavirenz. 2nd Inter-national Workshop on HIV Drug-Resistance and Treatment Strategies. Lake Maggiore, Italy (24–27 June 1988). Abstract19.
   Google Scholar
• HSIOU Y, DAS K, DING J et al.: Crystal structures of wild-type and mutant 11IV-1 reverse transcriptase and non nucleoside inhibitors: implications for drug resis-tance mechanisms. 2nd International Workshop on HIV Drug-Resistance and Treatment Strategies. Lake Maggiore, Italy (24–27 June 1998). Abstract 21.
   Google Scholar
• CORBETT JW, KO SS, ERICKSON-VIITANEN S et al.: Dis-covery of 11IV-1 non-nucleoside reverse transcriptase development candidates DMP 961 and DMP 963. AIDS (1998) 12(4):523.
   Google Scholar
• ERAKER SD, KIRSCHT JP, BECKER MH: Understanding and improving adherence. Ann. Intern. Med. (1984) 100:258–286.
   PubMed Web of Science ®Google Scholar
• MEICHENBAUM D, TURK DC: Treatment and adherence:terminology, incidence and conceptualisation. In: Fa-cilitating Treatment Adherence. Plenum, New York, USA (1987):19–39.
   Google Scholar
• HAYNES RB: Determinants of adherence: the disease and the mechanics of treatment. In: Adherence in Healthcare. RB Haynes, DW Taylor, DC Sackett (Eds.) John Hopkins University Press, Baltimore, USA (1979):49–62.
   Google Scholar
• DIMATTEO MR, FRIEDMAN HS: Social Psychology and Medicine. Oelgeschlager, Gunn and Hain, Cambridge, MA (1982):35–58.
   Google Scholar
• CONRAD P: The meaning of medications: another lookat adherence. Soc. ScL Merl. (1985) 20(1):29–37.
   PubMed Web of Science ®Google Scholar
• BECKER MH, MAIMAN LA: Strategies for enhancing ad-herence. J. Community Health (1980) 6:113–135.
   PubMedGoogle Scholar
• SINGH N, SQUIER C, SIVEK C, WAGENER M et al.: Deter-minants of adherence with antiretroviral therapy in patients with human immunodeficiency virus: pro-spective assessment with implications for enhancing adherence. AIDS Care (1996) 8(3):261–269.
   PubMed Web of Science ®Google Scholar
• ELDRED L, WU A, CHAISON RE, MOORE RD: Adherence to antiretroviral therapy in HIV disease. 4th Conference on Retroviruses and Opportunistic Infections, Washington, USA (22–26 Jan. 1997). Abstract 251.
   Google Scholar
• GRIFFITH S: A review of factors associated with patient adherence and the taking of prescribed medicines. Br. J. Gen. Prac. (1990) 40:114–116.
   PubMed Web of Science ®Google Scholar
• EISEN S, MILLER D, WOODWARD R et al.: The effect of prescribed daily dose frequency on patient medica-tion compliance. Ann. Intern. Merl. (1990)150:1881–1884.
   Web of Science ®Google Scholar
• RUDD P, AHMED S, ZACHERY V et al: Improved compli-ance measures: applications in an ambulatory hyper-tensive trial. Clin. Pharmacol. Ther. (1990) 48:676–685.
   PubMed Web of Science ®Google Scholar
• BLASCHKE TF: Noncompliance and resistance to prote-ase inhibitors. 4th Conference on Retroviruses and Oppor-tunistic Infections. Washington, USA (22–26 Jan. 1997). Abstract S43.
   Google Scholar
• RIDDLER S, KAHN J, HICKS C et al.: Durable clinical anti-11IV-1 activity (72 weeks) and tolerability for efavirenz (DMP 266) in combination with indinavir (IDV) [DMP 266–003, Cohort IV]. 12th World AIDS Conference. Ge-neva, Switzerland (28 June-3 July 1998). Abstract 12359.
   Google Scholar
• MAYERS D, JEMSEK J, EYSTER E et al.: A double blind,placebo-controlled study to assess the safety, tolerabil-ity and antiviral activity of efavirenz (EFV, Sustiva, DMP 266) in combination with open-label zidovudine (ZDV) and lamivudine (3TC) in 11IV-1 infected patients [DMP 266-004]. 12th World AIDS Conference. Geneva, Switzerland (28 June-3 July 1998). Abstract 22340.
   Google Scholar
• HAAS DW, SEEKINS D, COOPER R et al.: A Phase II, dou-ble blind, placebo-controlled, dose ranging study to as-sess the antiteroviral activity and safety of efavirenz (EFV, Sustiva, DMP 266) in combination with open-label zidovudine (ZDV) and lamivudine (3TC) at 36 weeks [DMP 266-005].]. 12th World AIDS Conference. Ge-neva, Switzerland (28 June-3 July 1998). Abstract 22334.
   Google Scholar
• ERON J, PETERSON D, MURPHY R et al.: An open-label, randomized, comparative study of stavudine + didano-sine + indinavir versus zidovudine + lamivudine + indinavir in treatment naïve HIV-infected patients. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1–5 Feb. 1998). Abstract 381.
   Google Scholar
• GULICK RM, MELLORS JW, HAVLIR D et al.: Treatmentwith indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New Engl. J. Med. (1997) 337:743–739.
   Google Scholar
• HAMMER SM, SQUIRES KE, HUGHES MD et al: A con- trolled trial of two nucleoside analogues plus indina-vir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millime-ter or less. New Engl. J. Med. (1997) 337:725–733.
   PubMed Web of Science ®Google Scholar
• ••Studies which established the PI therapy paradigm.
   Google Scholar
• GAZZARD BG, MOYLE GJ: On behalf of the BHIVA Guideline Writing Committee 1998 revision to the Brit-ish HIV association guidelines for antiretroviral treat-ment of HIV seropositive individuals. Lancet (1998) 352:314–316.
   PubMed Web of Science ®Google Scholar
• STASZEWKI S, MORALES-RAMIREZ J, TASHIMA K et al. A Phase III, multicenter, randomized, open-label study to compare the antiviral activity and tolerability of efavirenz (EFV) + indinavir (IDV) versus EFV + zidovu-dine (ZDV) + lamivudine (3TC) versus IDV + ZDV + 3TC at 24 weeks [DMP 266-006]. 12th World AIDS Conference. Geneva, Switzerland (28 June-3 July 1998) Abstract 22336
   Google Scholar
• TASHIMA K, STASZEWKI S, MORALES-RAMIREZ J et al.: A Phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV) versus EFV + Zi-dovudine (ZDV) + lamivudine (3TC) versus IDV + ZDV + 3TC at 36 weeks [Study 006]. 6th Conference on Retrovi-ruses and Opportunistic Infections. Chicago, USA (31 Jan.-5 Feb. 1999). Abstract LB–16.
   Google Scholar
• ••Presentations of the head-to-head comparison of indinavir-vs. efavirenz-based triple therapy.
   Google Scholar
• MOYLE GJ: Editorial review: treatment guidelines and clinical realities. Curr. Opin. Infect. Dis. (1999) 12: 1–3.
   PubMed Web of Science ®Google Scholar
• FESSEL WJ, HAAS DW, DELAPENHA RA et al.: A Phase III, double-blind, placebo-controlled, multicenter study to determine the effectiveness and tolerability of the combination of efavirenz (EFV, Sustiva, DMP 266) and indinavir (IDV) versus indinavir in 111V-1 infected pa-tients receiving nucleoside analogue (NRTO therapy at 24 weeks. 12th World AIDS Conference. Geneva, Switzer-land (28 June-3 July 1998). Abstract 22343.
   Google Scholar
• MILD VAN D, MARTIN G, EYSTER M et al: Initial effective-ness and tolerability of nelfinavir (NFV) in combination with efavirenz (EFV, Sustiva, DMP 266) in antiretroviral naive and nucleoside analogue experi-enced 111V-1 infected patients: characterisation in a Phase II, open-label, multicenter study at 16 weeks [DMP 266-024]. 12th World AIDS Conference. Geneva, Switzerland (28 June-3 July 1998). Abstract 22386.
   Google Scholar
• ALBRECHT M, KATZENSTEIN D, BOSCH RJ et al.: ACTG 364: Virologic efficacy of nelfinavir and/or efavirenz in combination with new nucleoside analogs in nu-cleoside experienced subjects. 12th World AIDS Confer-ence. Geneva, Switzerland (28 June-3 July 1998). Abstract 12203.
   Google Scholar
• ••Key study of efavirenz in second-line regimens.
   Google Scholar
• SQUIRES K, HAMMERS, DEGRUTTOLA V et al: Random- ized trial of abacavir (ABC) in combination with indi-navir (IDV) and efavirenz (EFV) in HIV-infected patients (Pts) with nucleoside analog experience (NRTI exp). 6th Conference on Retroviruses and Opportun-istic Infections. Chicago, USA (31 Jan.-4 Feb. 1999). Abstract LB–15.
   Google Scholar
• REIJERS MHE, WEVERLING GJ, JURRIAANS S et al.: Viral suppression with maintenance therapy after quadru-ple induction therapy in 111V-1 infected individuals: Amsterdam duration of antiretroviral medication (ADAM) study. Lancet 352:185–190.
   Google Scholar
• HAVLIR DV, MARSCHNER IC, HIRSCH MS et al.: Mainte-nance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. New Engl. J. Merl. (1998) 339:1261–1268.
   PubMed Web of Science ®Google Scholar
• MOYLE G, BALDWIN C, DENT N, GAZZARD B: Manage-ment of indinavir-associated metabolic changes by substitution with efavirenz in virologically controlled HIV + persons. 6th Conference on Retroviruses and Oppor-tunistic infections. Chicago, USA (31 Jan.-4 Feb. 1999). Ab-stract 669.
   Google Scholar
• •First switch study evaluating benefits on lipodystrophy. Graeme J Moyle Associate Director of HIV Research, Chelsea and Westminster Hospital, 369 Fulham Rd, London SW10 9NH, UK
   Google Scholar